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Abstract
Introduction: Infliximab, an antibody against tumor necrosis factor alpha, is used to treat inflammatory bowel
disease and has well-established efficacy and proven safety. Complications of this treatment are related to
immunosuppression and include higher risk of serious infections and malignant neoplasia. Although extremely rare,
fulminant liver damage related to infliximab therapy has been reported.
Case presentation: We present the case of a 38-year-old Afro-Brazilian woman with refractory ulcerative colitis
who was started on infliximab. She had no previous history of liver disease, alcohol abuse, or infection. After the
fifth dose of the medication, drug-induced liver injury was diagnosed. Treatment was discontinued but our patient’s
condition was aggravated by severe cholestasis and grade III/IV encephalopathy, requiring liver transplantation.
Conclusion: Drug-induced liver injury is an uncommon complication of infliximab. Current consensus recommends
screening for liver dysfunction prior to and during therapy. This case emphasizes the need for vigilance and
highlights a rare and potentially lethal complication.
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Introduction
Antibodies against tumor necrosis factor alpha, such as
infliximab (IFX), are increasingly being used to treat in-
flammatory bowel disease [1, 2]. They were originally
used to manage moderate to severe active Crohn’s dis-
ease but have recently been approved for severe ulcera-
tive colitis (UC) [3]. The most worrisome adverse effects
of IFX are the increased risks of developing serious in-
fections and malignancies; therefore, close monitoring of
patients is required to increase safety. Although uncom-
mon, IFX therapy has been associated with drug-
induced liver injury, which frequently occurs 13 weeks
after its initiation but may be diagnosed up to 6 months
later [4–11]. We report a rare case of severe UC treated
with IFX that was complicated by fulminant hepatic fail-
ure and required urgent liver transplantation.
Case presentation
A 38-year-old Afro-Brazilian woman with refractory UC
was started on IFX (5 mg/kg). Her baseline liver and renal
functions were entirely normal. Our patient became
asymptomatic after IFX-induction therapy (weeks 0, 2,
and 6). After the fifth dose of infliximab, routine labora-
tory examinations showed an increase in transaminases
levels, with aspartate aminotransferase (AST) of 325 U/L
and alanine aminotransferase (ALT) of 408 U/L, and the
medication was discontinued. Our patient had no history
of alcohol abuse or infection. Serology tests for hepatitis B
and C viruses, human immunodeficiency virus (HIV),
cytomegalovirus, and Epstein–Barr virus were negative.
No serum smooth-muscle, anti-nucleic, or antimitochon-
drial antibodies could be detected. Even after we discon-
tinued therapy, our patient’s condition worsened. She
developed severe cholestasis with marked jaundice and fa-
tigue, requiring hospitalization. Laboratory tests were as
follows: bilirubin 23.38 mg/dL (normal range <1.2 mg/dL),
AST 1,254 U/L (normal range <35 U/L), and ALT 2,177 U/L
(normal range <105 U/L). Her platelet count decreased to
54,000 and the plasma internationalized normalized ratio
(INR) was elevated to a value of 4.1. A nuclear magnetic
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resonance scan demonstrated acute liver damage. She de-
veloped grade III encephalopathy with marked confusion
and incomprehensible speech and had an emergency
whole liver transplantation. The surgery was successful. A
histopathological analysis of her explanted liver revealed
extensive necrosis compatible with fulminant hepatic fail-
ure (Fig. 1). After the procedure, results from hepatic tests
normalized (Fig. 2). Our patient made a full recovery and
is receiving immunosuppressive therapy with tacrolimus.
No signs of liver rejection or colitis reactivation have yet
been noted.
Discussion
The number of patients treated with IFX has rapidly in-
creased worldwide. An estimated 2 million people were
exposed to this drug from 1998 to 2014. The colectomy
rate in UC significantly decreased after the introduction
of this class of drugs [12–15]. Despite this notable suc-
cess, physicians must be aware of the possible complica-
tions, especially those related to immunosuppression
such as serious infections and malignant neoplasia.
Elevated liver enzymes (especially ALT) have been re-
ported during IFX treatment but are usually transitory
and have no clinical implications. Fulminant liver failure is
an extremely rare and serious event that requires a liver
transplant, with high morbidity and mortality [16–18].
IFX-induced acute liver failure may be explained in three
possible ways: autoimmune hepatitis, cholestatic injury,
and direct toxicity [19].
In the present case, our patient had no history of al-
cohol consumption or concomitant use of any hepato-
toxic drugs. Serological tests for infectious hepatitis,
HIV, or other viruses were negative. Autoimmune dis-
ease was also excluded. Histopathological analysis of
the explanted liver evidenced diffuse hepatitis inter-
twined with areas of necrosis, suggesting direct liver
damage. A diagnosis of IFX-induced hepatitis was made
considering the temporal relationship with IFX expos-
ure, lack of other possible causes of liver injury, labora-
tory changes, and clinical deterioration.
Current guidelines support screening for liver dysfunc-
tion at 4-month intervals. It is also important to rule out
any hepatotoxic risk factor prior to IFX therapy. Discon-
tinuation of IFX is recommended if transaminase levels
reach three times the upper normal limits, especially if
associated with clinical manifestations [20].
Conclusion
This report calls attention to a rare and potentially lethal
adverse effect of IFX. All efforts should be made to rule
out any pre-existing liver disease before initiating IFX
therapy and vigilance must continue during the mainten-
ance treatment, which must be interrupted if aminotrans-
ferases elevate more than three times above the normal
levels. Signs of abrupt clinical deterioration should raise
suspicion for fulminant liver disease.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
Fig. 1 Hepatic necrosis. Hematoxylin and eosin staining, original magnification 10×
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